GSE162696 L-13 3 v 1 human up (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE162696_L-13_3_v_1_human_up.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE162696_L-13_3_v_1_human_up.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE162696_L-13_3_v_1_human_up.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE162696_L-13_3_v_1_human_up.

Results found

Linked to

 

Label

Description

 

Gene

long intergenic non-protein coding RNA 2367

Gene

chromosome 8 putative open reading frame 44

Gene

uncharacterized LOC101929130

Gene

ribosomal protein L18a pseudogene 4

Gene

zinc finger protein 772 pseudogene

Gene

PPM1K divergent transcript

Gene

long intergenic non-protein coding RNA 2387

Gene

ribosomal protein L9 pseudogene 25

Gene

collagen alpha-1(XVI) chain

Gene

R3H domain containing 2 pseudogene 2

  • Gene

    long intergenic non-protein coding RNA 2367


  • Gene

    chromosome 8 putative open reading frame 44


  • Gene

    uncharacterized LOC101929130


  • Gene

    ribosomal protein L18a pseudogene 4


  • Gene

    zinc finger protein 772 pseudogene


  • Gene

    PPM1K divergent transcript


  • Gene

    long intergenic non-protein coding RNA 2387


  • Gene

    ribosomal protein L9 pseudogene 25


  • Gene

    collagen alpha-1(XVI) chain


  • Gene

    R3H domain containing 2 pseudogene 2

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.